cancer vaccines
-
Moderna Puts Up $120M to Start Cancer Drug R&D Alliance With Immatics
Moderna and Immatics aim to see if the combination of their respective technologies can lead to better cancer treatments spanning multiple therapeutic modalities. Milestone payments to immunotherapy developer Immatics could top $1.7 billion.
-
Cancer Biotech Elicio Finds Path to Public Markets Via Angion Reverse Merger
Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Merck pays Moderna $250M to share equally in cancer vaccine for melanoma
Moderna and Merck have been partners in the development of messenger RNA cancer vaccines since 2016. Merck is deepening the alliance by exercising an option that enables it to share equally in further work on a partnered cancer vaccine for melanoma.
-
mRNA vaccines a potentially life-saving therapeutic option for people with occupational cancer
Notwithstanding significant progress made in the past decade in the fight against cancer, this disease remains the world’s second-largest cause of death, behind cardiovascular disease. Now, mRNA cancer vaccines could offer some hope.
-
Biotech startup raises $25M for cancer, Covid-19 vaccines
Vaccines developed by Aivita Biomedical use a patient’s own blood to attack cancer and Covid-19. But the company also offers a consumer skin-care product that it plans to begin selling more widely.
-
Key takeaways from BioNTech CEO’s JPM presentation
Ugur Sahin presented a sweeping vision of the company’s goal to become a next-generation immunotherapy company leveraging the messenger RNA platform technology that has won it acclaim and financial returns during the Covid-19 pandemic.
-
Boehringer Ingelheim to acquire Swiss cancer vaccine developer for up to 325M euros
The deal includes an upfront payment and up to 100 million euros in milestones, equaling $364.5 million. Amal’s lead candidate is a vaccine for colorectal cancer expected to enter the clinic later this month.
-
BioPharma, Pharma, Startups, SYN
PsiOxus doubles-down with BMS in $936M deal
PsiOxus Therapeutics has signed a second agreement with Bristol-Myers Squibb (BMS), this time for worldwide rights to its ‘armed’ oncolytic virus NG-348, currently in the preclinical research phase.
-
Oncolytic immunotherapy startup BeneVir gets $3M
BeneVir’s cancer vaccines are engineered to incite an immune response, as well as hide from the immune system – so as to have a prolonged anti-cancer effect.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.